Tao Li

Tao Li


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2023 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
QSQiyang Shen
Qiyang Shen
XLXingyu Liu
Xingyu Liu
SPSirui Pan
Sirui Pan
TLTao Li
Tao Li
JZJianfeng Zhou
Jianfeng Zhou

23 March 2024 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
SPSirui Pan
Sirui Pan
QSQiyang Shen
Qiyang Shen
JZJianfeng Zhou
Jianfeng Zhou
TLTao Li
Tao Li
Tumor lysis syndrome (TLS) is a hematologic oncological emergency characterized by metabolic and electrolyte imbalances. On breakdown of tumor cells, enormous amounts of potassium, phosphate, and nucleic acids are released into systemic circulation. TLS mainly occurs during chemotherapy. However, there are rare incidences of spontaneous tumor lysis syndrome (STLS) prior to commencement of therapy. In the case being reported, the child had just undergone a biopsy. As the incision was being closed, there was a sudden onset of high fever, arrhythmia, severe hyperkalemia, hypocalcemia, and acidosis. Following timely symptomatic treatment and continuous renal replacement therapy(CRRT), the child’s laboratory results improved, and organ function was restored to normal. The final pathological diagnosis confirmed Burkitt lymphoma. The boy is currently on maintenance chemotherapy. TLS is a potentially life-threatening complication in hematologic oncology. Several important conclusions can be drawn from this case, reminding clinicians to: (1) be fully aware of the risk factors of TLS and evaluate the level of risk; (2) pay attention to the possibility of STLS during operation, if surgical procedures are necessary and operate with minimal trauma and in the shortest time possibly; (3) take preoperative prophylaxis actively for high-risk TLS patients, including aggressive fluid management and rational use of diuretics and uric-acid-lowering drugs. In addition, this case confirms the effectiveness of CRRT for severe STLS.

2 May 2024 in Translational Pediatrics
Verified
Journal Article
Open access
PDF file
JLJian Li
Jian Li
LHLulu He
Lulu He
QWQizi Wu
Qizi Wu
JZJianfeng Zhou
Jianfeng Zhou
LZLi Zhou
Li Zhou
TLTao Li
Tao Li
Background: Undifferentiated embryonal sarcoma of the liver (UESL) is a rare and highly aggressive malignancy predominantly affecting children and adolescents. Managing UESL is particularly intricate due to its aggressive nature and the limited array of treatment options available. This study is dedicated to elucidating the efficacy of a multimodal therapeutic strategy in the successful management of UESL. Case Description: Four pediatric patients (two males, two females; aged 6–11 years) diagnosed with UESL were treated at the Children’s Hospital of Nanjing Medical University between November 2019 and June 2023. Surgical resection with lymph node dissection achieved complete primary tumor eradication. Adjuvant chemotherapy tailored to each patient’s needs was followed by localized radiation therapy. After 9–42 months of follow-up, one patient who did not undergo immediate radiotherapy experienced a relapse. Following a second operation coupled with radiotherapy, the patient achieved complete remission, and mirroring the status of the other three patients who are now presently in remission. The overall cohort exhibited commendable tolerance to the treatment regimen, with manageable chemotherapy-related toxicities. Conclusions: This case series suggests that implementing a standardized protocol of resection, followed by adjuvant chemotherapy and radiation, can lead to favorable outcomes in pediatric patients diagnosed with UESL. Nevertheless, the need for comprehensive large-scale studies is imperative to substantiate the effectiveness of this approach.

18 May 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
QSQiyang Shen
Qiyang Shen
XLXingyu Liu
Xingyu Liu
LZLijie Zhang
Lijie Zhang
TLTao Li
Tao Li
JZJianfeng Zhou
Jianfeng Zhou
A boy aged 55 months was diagnosed with stage IV Neuroblastoma (NB) of the right adrenal gland 2 years ago. Preoperative chemotherapy was given and he was then treated with retroperitoneal tumor resection and lymph node dissection. After surgery, the children were transferred to the Hemato-Oncology Department for chemotherapy according to the high-risk group NB, with outpatient follow-up every 6 months. In the second postoperative year, abdominal computed tomography (CT) scan revealed a rounded hypodense area in the upper part of the right posterior lobe of the liver, with marked inhomogeneous enhancement in the venous phase after enhancement, which was surgically resected, and postoperative pathology confirmed inflammatory myofibroblastic tumor (IMT) of liver. The patient was not given any special treatment after surgery. In this study, whole transcriptome sequencing was performed on the postoperative specimen of adrenal NB and the specimen of IMT of liver. This unusual case emphasizes the need for close monitoring of second tumor development in NB survivors even in the absence of known predisposing factors.

16 February 2024 in Gene
Verified
Journal Article
Closed access
JZJianfeng Zhou
Jianfeng Zhou
XLXingyu Liu
Xingyu Liu
HYHanjun Yin
Hanjun Yin
YZYong Zhou
Yong Zhou
ZXZhongya Xu
Zhongya Xu
QSQiyang Shen
Qiyang Shen

4 August 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
THTianjiao Hu
Tianjiao Hu
JLJian Li
Jian Li
LHLulu He
Lulu He
XZXiaojun Zhang
Xiaojun Zhang
JXJin Xu
Jin Xu
LZLi Zhou
Li Zhou
Anti-Ganglioside (GD)2 monoclonal antibodies are widely used as maintenance therapy for high-risk neuroblastoma (HR-NB). However, the potential benefit of introducing immunotherapy during induction chemotherapy remains unclear. We report two pediatric patients with newly diagnosed HR-NB who received naxitamab in combination with chemotherapy starting from the second cycle of induction. Clinical characteristics, treatment regimens, and outcomes were retrospectively reviewed. Both patients achieved complete remission (CR) per International Neuroblastoma Response Criteria at the end of induction. Treatment-related adverse events, including hypotension, pain, and rash, capillary leak syndrome, and chemotherapy-related myelosuppression, were transient and manageable with supportive care and infusion adjustments. No treatment discontinuation due to toxicity occurred. While these preliminary findings demonstrate the feasibility and tolerability of early naxitamab introduction, the limited sample size precludes definitive conclusions regarding efficacy. This report provides exploratory data to support future prospective studies on optimizing the timing of anti-GD2 immunotherapy in HR-NB.